Alnylam Pharmaceuticals Earnings & Forecasts

Alnylam Pharmaceuticals (ALNY) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

분기별 실적 서프라이즈 금액

회계 분기	보고된 날짜	실제 EPS	예상 EPS	놀라다 %
Q2	Jul 30, 2026	$1.84	$2.00	-8.00 %
Q1	Apr 30, 2026	$1.99	$1.36	46.3 %
Q4	Feb 12, 2026	$1.25	$1.20	4.17 %
Q3	Oct 30, 2025	$2.90	$1.23	135.8 %

Quarterly Revenue (Billions)

분기별 수익 깜짝 금액

회계 분기	보고된 날짜	실제 수익	예상 수익	놀라다 %
Q2	Jul 30, 2026	$1.29B	$1.32B	-2.02 %
Q1	Apr 30, 2026	$1.17B	$1.12B	4.26 %
Q4	Feb 12, 2026	$1.10B	$1.15B	-4.64 %
Q3	Oct 30, 2025	$1.25B	$992.47M	25.9 %

Alnylam Pharmaceuticals Guidance

Alnylam Pharmaceuticals (ALNY)는 7월 30, 2026에 fiscal year 2026에 대한 가이던스를 마지막으로 발표했습니다. 회사는 해당 기간의 매출을 $5.28B - $5.72B 범위로 예상했습니다.

이전 가이던스와 비교하여 Alnylam Pharmaceuticals는 매출 전망치를 이전 범위인 유지됨에서 $5.3B - $5.8B로 상향 조정했습니다.

Alnylam Pharmaceuticals은 16과 10월 27, 2022 사이에 7월 30, 2026개의 지침 업데이트를 발표했습니다. During this period, the company raised its outlook 7 times, reflecting management's growing confidence in business performance.

Recent Earnings Results

Metric	Q2 '26	Q1 '26	Q4 '25	Q3 '25
Earnings Per Share (Non-GAAP)
Estimate	$2.00	$1.36	$1.20	$1.23
Actual	$1.84	$1.99	$1.25	$2.90
Surprise	-8.00%	+46.3%	+4.17%	+135.8%
Revenue
Estimate	$1.32B	$1.12B	$1.15B	$992.5M
Actual	$1.29B	$1.17B	$1.10B	$1.25B
Surprise	-2.02%	+4.26%	-4.64%	+25.9%

Analyst Estimates — Forward PeriodsSource: Wall Street consensus

Metric	Q3 '26E	Q4 '26E	Q1 '27E	Q2 '27E
Earnings Per Share (Non-GAAP)
Consensus	$2.19	$2.61	$2.01	$2.49
Revenue
Consensus	$1.44B	$1.58B	—	—

More with Benzinga EdgeGet Access

Alnylam Pharmaceuticals Inc